Agenus has entered into three new deals with Targovax, Oxford BioTherapeutics, and Immunogenesis, respectively, doubling its current number of clinical collaborations.
Agenus, an immuno-oncology company, announced that it had entered into three new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis on May 31, 2022. These moves double its current number of collaborations, which now include Agenus clinical assets such as botensilimab, balstilimab, and zalifrelimab.
According to a company press release, Agenus is pursuing partnerships with companies developing agents with complementary mechanisms. Through this, they can work toward promising immunotherapy combinations to address immunosuppression in the tumor microenvironment. These combination studies are sponsored and executed by the companies’ collaborators, while drug supply and scientific support is provided by Agenus.
The collaboration will see three new clinical trials take place:
“These new collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis are exciting next steps in our partnership strategy to broaden combinations and indications under evaluation with our immunomodulatory antibodies,” said Steven O’Day, chief medical officer, Agenus, in the press release. “We believe these combinations may unlock the power of immunotherapy more broadly, potentially offering new and promising benefit to patients with treatment-resistant solid tumors.”
Source: Agenus
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.